Business Context and Reporting Period
Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 31, 2024
Business Overview: The Company operates through two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care products). All share and per-share data reflect a four-for-one stock split effected on February 16, 2024.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales | $1,002.8 | $930.2 | $2,877.0 | $2,666.1 |
| Gross Profit | $663.0 | $610.0 | $1,918.0 | $1,751.4 |
| Gross Margin | 66.1% | 65.6% | 66.7% | 65.7% |
| Operating Income | $192.5 | $151.6 | $507.3 | $397.4 |
| Net Income | $104.7 | $85.3 | $274.8 | $209.7 |
| Diluted EPS | $0.52 | $0.43 | $1.37 | $1.05 |
| Operating Cash Flow (9M) | $441.2 | $433.3 | - | - |
| Total Debt | $2,632.4 | $2,569.2 | - | - |
| Cash & Equivalents | $109.7 | $120.8 | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.8% in Q3 and 7.9% for the nine months ended July 31, 2024, compared to the prior year. Growth was driven by both segments, partially offset by unfavorable foreign exchange impacts of approximately $13.1 million (Q3) and $19.8 million (9M) for CooperVision, and $3.0 million (Q3) and $9.7 million (9M) for CooperSurgical.
- Segment Performance:
- CooperVision: Net sales rose 7% in Q3. Toric and multifocal lenses grew 10%, while spherical lenses grew 5%.
- CooperSurgical: Net sales rose 9% in Q3. Office and surgical sales increased 11%, and fertility sales increased 6%. The segment's operating income improved significantly (120% increase in Q3) compared to the prior year, which included a $45.0 million termination fee accrual related to a Cook Medical asset purchase agreement.
- Profitability: Operating income increased 27% in Q3 and 28% for the nine months. The effective tax rate increased to 36.1% in Q3 (from 28.2% in Q3 2023) and 33.6% for the nine months (from 31.6%), primarily due to changes in the geographic mix of earnings and a UK statutory tax rate increase from 19% to 25%.
- Acquisitions: The Company acquired a fertility company specializing in sperm separation devices for $33.5 million in June 2024. Subsequent to the quarter end, on August 1, 2024, the Company acquired obp Surgical for approximately $100.0 million.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term prospects in contact lens and general healthcare markets. They anticipate lower contact lens wearer dropout rates due to technology improvements and continued growth in single-use modalities.
- Liquidity: The Company believes current cash, operating cash flows, and availability under its 2024 Credit Agreement ($1.2 billion available) are sufficient to meet needs for at least 12 months. On May 1, 2024, the Company entered a new $2.3 billion revolving credit facility, replacing the 2020 agreement.
- Capital Allocation: No share repurchases were made in the first nine months of fiscal 2024; $256.4 million remains authorized. The semiannual dividend was discontinued in December 2023.
- Risks: Key risks include global economic instability, foreign currency fluctuations, supply chain disruptions (specifically silicone hydrogel components), regulatory changes (EU MDR/IVDR), and integration challenges from acquisitions.
Investor Verification Checklist
- Acquisition Integration: Verify the financial impact and integration progress of the Cook Medical assets (acquired Nov 2023) and the recent obp Surgical acquisition (Aug 2024).
- Foreign Exchange Impact: Monitor the sensitivity of earnings to currency fluctuations, which negatively impacted sales by over $20 million in the first nine months.
- Tax Rate Volatility: Confirm the sustainability of the effective tax rate given the UK rate increase and geographic earnings mix.
- Debt Servicing: Review interest expense trends given the higher debt balances and interest rates on the new 2024 Credit Agreement (weighted average 6.57% on revolver).
- Regulatory Approvals: Track progress on myopia management products (MiSight) and other R&D projects driving future growth.